Federal Register of Legislation
Statement of Principles concerning ATRIAL FIBRILLATION AND ATRIAL FLUTTER (Balance of Probabilities) (No. 2 of 2023) The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.
Dated 23 December 2022
The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
Professor Terence Campbell AM Chairperson
Contents 1 Name....................................................3 2 Commencement.............................................3 3 Authority..................................................3 4 Repeal...................................................3 5 Application................................................3 6 Definitions................................................3 7 Kind of injury, disease or death to which this Statement of Principles relates.....3 8 Basis for determining the factors..................................4 9 Factors that must exist.........................................4 10 Relationship to service.........................................11 11 Factors referring to an injury or disease covered by another Statement of Principles.12 Schedule 1 - Dictionary..............................................13 1 Definitions................................................13
1 Name This is the Statement of Principles concerning atrial fibrillation and atrial flutter (Balance of Probabilities) (No. 2 of 2023). 2 Commencement This instrument commences on 23 January 2023. 3 Authority This instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986. 4 Repeal The Statement of Principles concerning atrial fibrillation and atrial flutter No. 50 of 2014 (Federal Register of Legislation No. F2014L00482) made under subsection 196B(3) of the VEA is repealed. 5 Application This instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies. 6 Definitions The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument. 7 Kind of injury, disease or death to which this Statement of Principles relates (1) This Statement of Principles is about atrial fibrillation and atrial flutter and death from atrial fibrillation and atrial flutter. Meaning of atrial fibrillation and atrial flutter (2) For the purposes of this Statement of Principles: (a) atrial fibrillation means a disorder of cardiac rhythm, in which there is disorganised, rapid, and irregular atrial electrical activation, resulting in loss of organised atrial mechanical contraction and an irregular, usually rapid ventricular rate. (b) atrial flutter: (i) means a disorder of cardiac rhythm in which there is rapid and regular atrial electrical activation caused by a re-entry circuit within the right atrium, resulting in a regular, rapid atrial rate; and (ii) a characteristic electrocardiographic appearance of a uniform and regular continuous sawtooth wave-form. Note 1: Atrial fibrillation and atrial flutter can be paroxysmal, persistent or permanent disorders, with variable electrocardiographic and clinical features. Ventricular rates in atrial flutter are typically 150 beats per minute. Note 2: Symptoms of atrial fibrillation or atrial flutter typically include palpitations, fatigue, lightheadedness, and mild shortness of breath. Less common problems include significant dyspnoea, angina, hypotension, anxiety and syncope. Note 3: Atrial fibrillation and atrial flutter can occur alone or in combination. (3) While atrial fibrillation and atrial flutter attract ICD‑10‑AM code I48, in applying this Statement of Principles the meaning of atrial fibrillation and atrial flutter is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4. Death from atrial fibrillation and atrial flutter (5) For the purposes of this Statement of Principles, atrial fibrillation and atrial flutter, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's atrial fibrillation and atrial flutter. Note: terminal event is defined in the Schedule 1 – Dictionary. 8 Basis for determining the factors On the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that atrial fibrillation and atrial flutter and death from atrial fibrillation and atrial flutter can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA. Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary. 9 Factors that must exist At least one of the following factors must exist before it can be said that, on the balance of probabilities, atrial fibrillation and atrial flutter or death from atrial fibrillation and atrial flutter is connected with the circumstances of a person's relevant service: (1) having valvular heart disease at the time of the clinical onset of atrial fibrillation or atrial flutter; Note 1: valvular heart disease is defined in the schedule 1 Dictionary. (2) having ischaemic heart disease at the time of the clinical onset of atrial fibrillation or atrial flutter; (3) having non-infectious myocarditis at the time of the clinical onset of atrial fibrillation or atrial flutter; Note 1: Non-infectious myocarditis can be acute or chronic. Note 2: Non-infectious myocarditis can be of autoimmune, infiltrative or immunological origin. Examples of causes of non-infectious myocarditis include immune checkpoint inhibitor therapy and giant cell myocarditis. (4) having viral myocarditis at the time of the clinical onset of atrial fibrillation or atrial flutter; Note 1: Viral myocarditis can be acute or chronic. Note 2: Examples of viral causes of myocarditis include severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue virus. (5) having a non-viral infection of the myocardium at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: Examples of causes of non-viral infection of the myocardium include Borrelia burgdorferi and leptospirosis. (6) having pericarditis at the time of the clinical onset of atrial fibrillation or atrial flutter; (7) having cardiomyopathy at the time of the clinical onset of atrial fibrillation or atrial flutter; (8) having heart failure at the time of the clinical onset of atrial fibrillation or atrial flutter; (9) having hypertension before the clinical onset of atrial fibrillation or atrial flutter; (10) having pulmonary thromboembolism within the 30 days before the clinical onset of atrial fibrillation or atrial flutter; (11) having a thyroid condition from the specified list of thyroid conditions at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: specified list of thyroid conditions is defined in the Schedule 1 – Dictionary. (12) consuming an average of at least 150 grams of alcohol per week for a continuous period of at least the 5 years before the clinical onset of atrial fibrillation or atrial flutter; Note: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink. (13) binge drinking within the 2 days before the clinical onset of atrial fibrillation or atrial flutter; Note: binge drinking is defined in the Schedule 1 – Dictionary. (14) having a thoracic surgical procedure or an invasive cardiac procedure within the 1 year before the clinical onset of atrial fibrillation or atrial flutter; Note 1: Examples of thoracic surgical procedures include vascular, mediastinal, pulmonary and chest wall surgery. Note 2: Examples of invasive cardiac procedures include: (a) coronary artery bypass grafting; (b) heart transplant; (c) open heart surgery; and (d) transcatheter aortic valve implantation. (15) having a non-cardiothoracic surgical procedure involving general or regional anaesthesia, within the 30 days before the clinical onset of atrial fibrillation or atrial flutter; Note: Examples of non-cardiothoracic surgical procedures include emergency or elective orthopaedic and abdominal surgery and neurosurgery. (16) having chronic obstructive pulmonary disease at the time of the clinical onset of atrial fibrillation or atrial flutter; (17) having asthma of sufficient severity to require maintenance therapy at the time of the clinical onset of atrial fibrillation or atrial flutter; (18) undertaking strenuous physical activity greater than 6 METs, for an average of at least 20 hours per week for a continuous period of at least the 5 years before the clinical onset of atrial fibrillation or atrial flutter; Note: MET is defined in the Schedule 1 – Dictionary. (19) inability to undertake any physical activity greater than 3 METs for at least the 1 year before the clinical onset of atrial fibrillation and atrial flutter; Note: MET is defined in the Schedule 1 - Dictionary. (20) having sick sinus syndrome at the time of the clinical onset of atrial fibrillation or atrial flutter; (21) having a benign or malignant neoplasm involving the cardiac atrium at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: A neoplasm involving the cardiac atrium can be primary or metastatic. An example of a primary neoplasm involving the heart is cardiac lymphoma. (22) having a non-neoplastic lesion involving the cardiac atrium at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: Examples of non-neoplastic lesions which can involve the cardiac atrium include cardiac tamponade and coronary artery aneurysm. (23) having a malignant neoplasm, excluding non-melanotic malignant neoplasm of the skin, at the time of the clinical onset of atrial fibrillation or atrial flutter; (24) undergoing a course of therapeutic radiation for cancer, where the heart was in the field of radiation, before the clinical onset of atrial fibrillation or atrial flutter; (25) having diabetes mellitus for at least the 5 years before the clinical onset of atrial fibrillation or atrial flutter; (26) experiencing penetrating trauma to the heart within the 1 year before the clinical onset of atrial fibrillation or atrial flutter; (27) having a spinal cord injury before the clinical onset of atrial fibrillation or atrial flutter; Note: spinal cord injury is defined in the Schedule 1 – Dictionary. (28) having sepsis, or an injury or illness requiring admission to an intensive care unit or mechanical ventilation within the 30 days before the clinical onset of atrial fibrillation or atrial flutter; Note: sepsis is defined in the Schedule 1 – Dictionary. (29) having infiltration of the myocardium due to amyloidosis or sarcoidosis at the time of the clinical onset of atrial fibrillation or atrial flutter; (30) having an autoimmune or inflammatory disease from the specified list of autoimmune or inflammatory diseases at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: specified list of autoimmune or inflammatory diseases is defined in the Schedule 1 - Dictionary. (31) being overweight or obese for at least the 5 years before the clinical onset of atrial fibrillation or atrial flutter; Note: being overweight or obese is defined in the Schedule 1 - Dictionary. (32) having obstructive sleep apnoea at the time of the clinical onset of atrial fibrillation or atrial flutter; (33) having smoked tobacco products in an amount of at least 10 pack-years before the clinical onset of atrial fibrillation or atrial flutter; and if smoking has ceased before the clinical onset of atrial fibrillation or atrial flutter, then that onset occurred within 5 years of cessation; Note: one pack-year is defined in the Schedule 1 - Dictionary. (34) having chronic renal failure at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: chronic renal failure is defined in the Schedule 1 - Dictionary. (35) having systemic chemotherapy for a malignant disease at the time of the clinical onset of atrial fibrillation or atrial flutter; Note: Examples of systemic chemotherapy for malignant disease include: (a) anthracyclines including doxorubicin; (b) HER2 inhibitors including trastuzumab; and (c) tyrosine kinase inhibitors including ibrutinib.
We try to embed the page this law was scraped from. If the site blocks framing, you still get the link and a local excerpt.
Last checked with source on —
Checking whether the official page can be embedded…
Plain-English simplify of this law: a short summary, key points, and both sides of the argument. Generated on first view via Replicate, then cached. Vote on what helps your study.
No study brief is cached for this law yet. Sign up to generate a plain-English brief.
Sign up to generate